Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 by 9 percentage ...

Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win.

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...